Author

K. Hyman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:human· 1 Approach:mechanistic / dynamical model· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Lujambio· 1 shared D. Pal· 1 shared D. Zeltsman· 1 shared G. Hannon· 1 shared I. Ibarra· 1 shared J. Huang· 1 shared L. Glassman· 1 shared M. Esposito· 1 shared

Activity by Year

2021-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Lujambio

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

An epigenetic switch regulates the ontogeny of AXL positive/EGFR-TKI resistant cells by modulating miR-335 expression

R. Sordella, D. Pal, P. Safaric Tepes, T. Lindsted, I. Ibarra, A. Lujambio, V. Jimenez Sabinina, S. Senturk, M. Miller, N. Korimerla, J. Huang, L. Glassman, P. Lee, D. Zeltsman, K. Hyman, , G. Hannon

The paper identifies an epigenetic mechanism regulating AXL-positive/Erlotinib-resistant cells through miR-335 expression, suggesting combinatorial therapies for EGFR-mutated NSCLC.

bioRxiv · Jan 6, 2021Cancer Biology